Total serum immunoglobulins against vaccine GI.4 and GII.4 VLPs
At both dose levels (50 µg and 150 µg VLPs, respectively), the rNV-2v vaccine candidate elicited a significant increase in total immunoglobulins against GI.4 Chiba 407 (1987) and GII.4 Aomori 2 (2006) VLPs (Anti-GI.4 and anti-GII.4 VLP total Ig responses. Total anti-GI.4 and anti-GII.4 VLP Ig responses by scheduled time for each treatment. Vaccine or placebo were administered on days 1 and 29. OD values were processed using a 4-parameter logistic fitting algorithm to the standard curve, allowing the determination of antibody concentration in the samples, expressed as EU/ml. Anti-GI.4 Antibody response to vaccine antigens expressed as Geometric Mean Titer (EU/ml) of anti-GI.4 and anti-GII.4 VLP total Ig at scheduled time points for each study group.CI, confidence interval; Geomean, geometric mean antibody concentration.*Geometric mean values are expressed as EU/ml (ELISA units per milliliter).